Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA MONICA, Calif. & LOS ANGELES--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies. Under the partnership, Kite and Appia Bio will develop chimeric antigen receptor (CAR)-enginee

Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer

Moderna

Regeneron Pharmaceuticals

All three have blockbuster products already on the market.

3 Biotech Stocks That Could Make You Richer in August (and Beyond)

Clean Harbors

Campbell Soup

Alphabet

Home Depot

Unilever

With social responsibility taking a greater role in politics and Wall Street, these ESG stocks may find favor in your portfolio. The post 7 Stocks to Buy for Responsibility and Sustainability appeared first on InvestorPlace.

7 Stocks to Buy for Responsibility and Sustainability

BioNTech SE

MAINZ, Germany & SANTA MONICA, Calif.--(BUSINESS WIRE)--BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility's assets and leases in Gaithersburg, MD, from Kite. The transaction was announced on July 19, 2021. The acquisition strengthens BioNTech's cell therapy pipeline by accelerating the individualized solid

BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

Gilead's Q2 y/y growth was largely driven by Veklury revenue. Oncology revenue is also ramping, up 90% y/y.

Gilead Oncology Franchise Adding To Growth Scenario

AbbVie

GlaxoSmithKline

Pfizer

Walgreens

The healthcare sector is chock-full of safe, sturdy income plays. But these five top-rated high-yield dividend stocks really stand out in the crowd.

5 High-Yield Dividend Stocks for Healthy Income

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a more than $200 million endowment to the Gilead Foundation to further the company's vision of creating a healthier world for all people. The Gilead Foundation, established in 2005, builds on the company's longstanding commitment to supporting underserved communities around the world. It aims to create impact in the community and society by encouraging a culture of giving, engaging in local communities an

Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program

There are several pluses for BioNTech in the deal.

Why Investors Should Like BioNTech's Latest Deal With Gilead

Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.

Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline

Amazon

Mastercard

Pinterest

Agios Pharmaceuticals

Chubb

Citrix Systems

Edwards Lifesciences

With the trading day nearly halfway over, the broad markets were pulling back into the weekend.

Amazon, Mastercard, Pinterest and More Friday Afternoon Analyst Upgrades and Downgrades

Gilead Sciences Inc (NASDAQ: GILD) reported Q2 sales of $6.2 billion +21% Y/Y, beating the consensus estimate of $6.07 billion, helped by solid demand for COVID-19 treatment remdesivir and hepatitis C virus products.  Its net profit was $1.52 billion for the quarter, compared with a loss of $3.34 billion a year earlier.

Gilead Sciences Exceeds Expectations As Remdesivir Success Cushions Slump In HIV Franchise

Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on Q2 2021 Results - Earnings Call Transcript

Gilead Sciences Inc. late Thursday swung to profit and reported rising sales thanks to its COVID-19 drug, but a revenue drop from two of its HIV drugs and ongoing concerns about the pandemic dragged the stock lower.

Earnings Results: Sales of Gilead's COVID-19 drug top $800 million

Gilead Sciences Inc on Thursday posted higher second-quarter earnings, helped by strong sales of its COVID-19 antiviral treatment, Veklury, as well as hepatitis drugs.

Strong COVID-19 drug sales help boost Gilead second-quarter results

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2021. “We maintained our positive momentum in the second quarter, with both a solid financial performance and strong progress across our increasingly diverse portfolio. Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic,” said Daniel O'Day, Chairman and Chief Executive Officer, Gile

Gilead Sciences Announces Second Quarter 2021 Financial Results

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.

Gilead (GILD) to Report Q2 Earnings: What's in the Cards?

Gilead Sciences Inc. (NYSE: GILD) was ordered to pay about $1.8 million late last week in attorney's fees and legal expenses to shareholders who sued the company after they were blocked from reviewing notable company records, according to Courthouse News Service.  Why It Matters: The information requests initially stemmed from the company using licensing agreements with rivals to slow generic competition to its HIV prevention drug.

Gilead Ordered To Pay Attorney Fees In Shareholder Lawsuit

Amgen

Bristol-Myers

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

Johnson & Johnson

Merck

Thermo Fisher Scientific

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Healthcare ETFs in Focus as Q2 Earnings Unfold

Eli Lilly

Vertex Pharmaceuticals

They have ample motivation and cash to gobble up a smaller company.

3 Biotechs That Could Make Big Acquisitions This Year

Shares of BioNTech SE were down 2.4% in premarket trading on Monday after the company said it plans to buy one of Gilead Sciences Inc.'s clinical manufacturing facilities and its platform for T-cell receptor therapies. The companies did not disclose financial terms of the deal, saying only that BioNTech will make a one-time payment for the platform and the facility in Gaithersburg, MD.

BioNTech to buy T-cell receptor facility and platform from Gilead Sciences

MAINZ, Germany & SANTA MONICA, Calif.--(BUSINESS WIRE)--BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite's solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will comple

BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

Gilead Sciences Inc (NASDAQ: GILD) announced new Phase 3 data from the ongoing CAPELLA trial evaluating lenacapavir, its investigational, long-acting HIV-1 capsid inhibitor.  The data were presented at the 11th International AIDS Society (IAS) Conference on HIV Science.

Gilead's Lenacapavir Shows High Rates Of Virologic Suppression In Heavily Treated HIV Patients

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a pooled analysis of a 48-week open-label extension of two Phase 3 studies (Study 1489 and Study 1490) shows 99% of participants who initiated treatment with Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) maintained an undetectable viral load (HIV-1 RNA

Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company's investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV. The findings demonstrate that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high rates of virologic suppression at Week 26

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

British American Tobacco

Medical Properties Trust

Safe high-yielding stocks can be found in both bull and bear markets alike. I present 3 picks that offer safety, growth, and diversification, as they reside in three vastly different sectors.

News for Gilead Sciences Stock (GILD)